This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Note on Biotech Business Development
Hamermesh, Richard G.; Higgins, Robert F.Case HBS-807032-EEntrepreneurshipTo maximize their effectiveness, color cases should be printed in color. Describes the business development process in biotechnology companies. Topics covered include: participants in the licensing process and their interests, the major steps in the licensing process, the terms that are part of most agreements, and the most contentious issues that arise in the implementation of licensing agreements. Includes color exhibits.Starting at €8.20
-
Cynthia Fisher and the Rearing of ViaCell, Teaching Note
Hamermesh, Richard G.; Higgins, Robert F.; Seefeld, ErinTeaching Note HBS-808115-ETeaching Note for [806002].Starting at €0.00
-
U.S. Food and Drug Administration
Higgins, Robert F.; Hamermesh, Richard G.; Fuller, Virginia A.Case HBS-807050-ELeadership and People ManagementDescribes the U.S. FDA with particular emphasis on its role in the development of new drugs, biologic products, and medical devices today. Provides context for the drug approval process by describing the FDA's history and organizational structure.Starting at €8.20
-
Computerized Provider Order Entry at Emory Healthcare
Hamermesh, Richard G.; McFarlan, F. Warren; Morgan, Michael; Keil, Mark; Katz, Andrew; LaBorde, DavidCase HBS-311061-EInformation TechnologiesThe Computerized Provider Order Entry at Emory Healthcare case presents one hospital system's efforts to implement computerized provider order entry (CPOE) across all of its hospitals and the challenges they faced in doing so. Issues such as standardizatiStarting at €8.20
-
General Electric, 1984 (Spanish Version)
Aguilar, Francis J.; Hamermesh, Richard G.; Brainard, Caroline E.Case HBS-302S36Knowledge and CommunicationDescribe los primeros cuatro años de permanencia de Jack Welch como CEO de las ofertas de General Electric Co. con las formas Welch ha tratado de actividades de estrategia y planificación del cambio de GE y sus intentos de hacer la empresa más empresarial.Starting at €8.20
-
Expanding Ecommerce at Technos
Teixeira, Thales S.; Deshpande, Rohit; Costas, Ruth; Zogbi, PriscillaCase HBS-517078-EMarketingTechnos was the market leader in the Brazilian watch market. Its CEO had made a firm commitment of evolving the company's marketing and commercial practices by focusing less on pushing product to retail clients and more on branding to end consumers to pull watches from retailers. In 2016, the company was about to re-launch its master brand's website. But the more time passed, the greater were the discrepancies between what the marketing, commerci...Starting at €8.20
-
Bloodbuy
Hamermesh, Richard G.; Norris, MichaelCase HBS-815114-EEntrepreneurshipIn 2015, Chris Godfrey, founder and CEO of Bloodbuy has to consider the best path to growth for his young company that is attempting to disrupt the blood donation industry.Starting at €8.20
-
Amylin Pharmaceuticals B
Hamermesh, Richard G.; Knoop, Carin-IsabelCase HBS-813091-EEntrepreneurshipSupplement for case 809011Starting at €8.20
-
Branding Yoga
Deshpande, Rohit; Herman, Kerry; Lobb, AnnelenaCase HBS-512025-EMarketingYoga, an ancient discipline, has become popular worldwide. The marketing of yoga and dispute over its origins have led to debate as to whether yoga should be branded at all. Some yoga instructors have gone so far as to copyright their varieties of yoga; others in the yoga community say it is a religious and/or spiritual practice and as such should not be claimed as intellectual property.Starting at €8.20
-
Novasys Medical
Hamermesh, Richard G.; Barley, LaurenCase HBS-810027-EEntrepreneurshipNovasys has developed a new medical device and procedure for the treatment of female stress urinary incontinence that is cheaper and can be performed in doctors' offices. In spite of FDA approval, the American Medical Association has been unwilling to approve the product for reimbursement. The case deals with the company's struggle to obtain a reimbursement code.Starting at €8.20